Forte Biosciences Inc. ( (FBRX) ) has released its Q3 earnings. Here is a breakdown of the information Forte Biosciences Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Forte Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related indications, with its headquarters in Dallas, Texas, and its stock traded on Nasdaq under the symbol FBRX.
In its latest earnings report for the quarter ending September 30, 2025, Forte Biosciences Inc. highlighted significant advancements in its clinical trials, including the commencement of a Phase 2 study for celiac disease following promising Phase 1b results. The company also continues to develop FB102 for non-segmental vitiligo and alopecia areata.
Financially, Forte Biosciences reported a net loss of $17.7 million for the third quarter of 2025, compared to a loss of $8.4 million in the same period last year. The company’s operating expenses increased significantly, primarily due to heightened research and development costs, which rose to $15.1 million from $5.7 million in the previous year. Despite these losses, the company successfully raised $75 million through a public offering, bolstering its cash reserves to $93.4 million.
Looking forward, Forte Biosciences plans to continue its focus on advancing FB102 through clinical trials, with management expressing confidence in the company’s ability to fund operations for at least the next twelve months. However, the company acknowledges the need for additional capital to sustain long-term growth and development efforts.